^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    decitabine (DNMT inhibitor) +
    Vesanoid (tretinoin) (Cytotoxic T lymphocyte stimulant, Telomerase inhibitor, Retinoic acid receptor agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Clinical Efficacy Analysis of the Low-Dose Decitabine in Combination with Cytarabine, All-Trans Retinoic Acid and Granulocyte Colony-Stimulating Factor for Patients with MDS-EB

    Published date:
    11/04/2021
    Excerpt:
    In this study, we evaluated the tolerance and efficacy of the combination of low-dose decitabine, cytarabine, all-trans retinoic acid and granulocyte colony-stimulating factor (DLAAG) for MDS-EB patients...we noted the complete response in patients with ASXL1, TP53 mutations or WT1 overexpression despite the concomitant presence of complex cytogenetic at diagnosis...
    DOI:
    10.1182/blood-2021-144631
    Trial ID:
    DLAAG